

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF FINANCIAL OFFICER**

This announcement is made by Alphamab Oncology (the “**Company**,” together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce the appointment of Mr. WANG Fei (王飛) (“**Mr. Wang**”) as the chief financial officer of the Company effective from March 16, 2026. Mr. Wang will be primarily responsible for the Group’s capital operations, investment and financing management and investor relations.

The biographical details of Mr. Wang are set out below:

Mr. Wang has accumulated over 20 years of experience in financial management and capital markets, including more than 15 years in the biopharmaceutical industry in China and overseas. Prior to joining the Group, Mr. Wang worked at AstraZeneca, as the chief financial officer of its China operation from January 2011 to October 2015 and as the director of finance of its respiration, immunology and inflammation department from January 2020 to April 2020. From October 2015 to December 2017, he served as vice president and chief financial officer of Shanghai Aikang Fulona Investment Management Co., Ltd. (上海愛康富羅納投資管理有限公司). From March 2018 to December 2019, he served as an executive director and the chief financial officer of China NT Pharma Group (中國泰凌醫藥集團), a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 1011). In April 2020, he joined 3SBio Inc. (三生製藥), a company listed on the Stock Exchange (stock code: 1530), and served as its chief financial officer until April 2023, where he was responsible for finance and accounting functions, overseeing financial reporting, managing investment and financing activities and handling investor relations.

Mr. Wang received a bachelor’s degree in management from Xinjiang University of Finance and Economics (新疆財經大學) in 1999 and an MBA jointly conferred by Shanghai Jiao Tong University (上海交通大學) and Euromed Marseille Ecole de Management (now known as KEDGE) in 2012. Mr. Wang is a certified public accountant in the People’s Republic of China.

The Company hereby announces that Mr. CHAI Bo (柴博) (“**Mr. Chai**”) has resigned as the Vice President of Capital Markets of the Company with effect from March 16, 2026 due to his other work commitments. Mr. Chai has confirmed that he has no disagreement with the Company and there are no matters that need to be brought to the attention of the Stock Exchange and the shareholders of the Company in connection with his resignation.

The Company would like to take this opportunity to express its appreciation for the valuable contributions of Mr. Chai towards the Company during his tenure of service and warmly welcome Mr. Wang for his new position.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, March 18, 2026

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.*